Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.58 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12845568 | 0.94 | KIF11 (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL6152116 | 0.85 | KMT2A (0.74) | NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL4087493 | 0.84 | RAB9A (0.66) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL29673494 | 0.84 | ALDH1A1 (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL11092496 | 0.83 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2TP53ALOX15 | |
| SCHEMBL6396790 | 0.83 | RAB9A (0.76) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL31090324 | 0.82 | GAA (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4105580 | 0.82 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL29484162 | 0.82 | MAPK1 (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL5062623 | 0.82 | PEPD (0.80) | NPC1RAB9AALDH1A1GLAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113906321-B | Polarizing plate, method for manufacturing same, and image display device | 住友化学株式会社 | 2024-10-15 | — | — | CN | claimed |
| US-20240262801-A1 | COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES | MONDEGO BIO, LDA. (PT) | 2024-08-08 | — | — | US | claimed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | claimed |
| CN-115926228-B | Protective layer, preparation method thereof and lithium ion battery | 蜂巢能源科技(无锡)有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-117946033-A | Preparation method for photo-promoted synthesis of urea compound | 兰州大学 | 2024-04-30 | — | — | CN | claimed |
| CN-115926228-A | Protective layer, preparation method thereof and lithium ion battery | 蜂巢能源科技(无锡)有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-111303554-B | PVC plastic and preparation method thereof | 温州市隆昌塑料有限公司 | 2022-06-14 | — | — | CN | claimed |
| CN-114057499-A | Sliding plate brick and preparation method thereof | 江苏盛耐新材料有限公司 | 2022-02-18 | — | — | CN | claimed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | claimed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | claimed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | claimed |
| EP-0858455-A4 | 4-OXA AND 4-THIA STEROIDS | MERCK & CO INC (US) | 2000-04-12 | — | — | EP | claimed |
| US-5998464-A | 4-Oxa and 4-thia steroids | MERCK & CO., INC. (US) | 1999-12-07 | — | — | US | claimed |
| US-5817802-A | IN IONIZING MEDIUM WITH A TRIALKYLSILANE | MERCK & CO., INC. (US) | 1998-10-06 | — | — | US | claimed |
| EP-0858455-A1 | 4-OXA AND 4-THIA STEROIDS | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | claimed |
| US-5777134-A | 4-oxa and 4-thia steriods | MERCK & CO., INC. (US) | 1998-07-07 | — | — | US | claimed |
| US-5696266-A | HYDROGENATING DELTA-5-STEROIDAL ENELACTAM DISSOLVED IN SOLVENT IN PRESENCE OF RHODIUM CATALYST | MERCK & CO., INC. (US) | 1997-12-09 | — | — | US | claimed |
| WO-1997015564-A1 | 4-OXA AND 4-THIA STEROIDS | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | claimed |
| WO-1996007643-A1 | PROCESS FOR THE STEREOSELECTIVE REDUCTION OF STEROID ENELACTAMS | MERCK & CO., INC. (US) | 1996-03-14 | — | — | WO | claimed |
| US-4285863-A | YELLOW-TO-RED ORGANIC PIGMENTS; PLASTICS AND FABRICS; PAINTS, ENAMELS, AND INKS | MONTEDISON S.P.A. (IT) | 1981-08-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262801-A1 | COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES | PPM1A, TH, PPM1G | NPC1 2925/4885RAB9A 2110/4885SMN1; SMN2 3686/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | NPC1 185/4885RAB9A 2032/4885SMN1; SMN2 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.